Well StudiedLongevityImmune

Thymogen

Thymagen

EW Dipeptide | Thymus Immune Bioregulator

Half-life

Not established

Chain length

2 amino acids

Reference frequency

Daily for 10-20 days, then break

Research overview

DoseGear research brief

Thymogen (EW dipeptide) is a Khavinson bioregulator consisting of glutamic acid and tryptophan, originally isolated from calf thymus extracts (Thymalin) in the late 1980s. Developed by Professor Vladimir Khavinson, it has been registered in Russia since 1990 in multiple forms including injectable solution, nasal spray, and topical cream. Thymogen modulates both humoral and cellular immunity, activates T-cell differentiation, and has demonstrated geroprotective (anti-aging) and antitumor activities in research studies.

Mechanism of action

Thymogen works through multiple immunomodulatory mechanisms: (1) activates T-cell differentiation and T-cell recognition of peptide-MHC complexes, (2) induces changes in intracellular cyclic nucleotide composition, (3) activates neutrophilic chemotaxis and phagocytosis, (4) normalizes T-lymphocyte concentrations and ratios (CD3+, CD4+, CD8+), (5) stimulates production of immunoglobulins (IgA, IgG, IgE, IgM), and (6) enhances lymphocyte differentiation receptor expression. Research suggests Thymogen may interact specifically with the AACG DNA sequence, affecting gene expression. The peptide is rapidly distributed to thymus, lymph nodes, liver, adrenals, and kidneys.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Glutamyl–tryptophan dipeptide associated with thymalin and Khavinson research.

What it is researched for

Experimental immune regulation through proposed immune-cell differentiation and signaling effects.

Research observation window

Not reported in the reviewed compound-specific evidence.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

No sourced lyophilized-vial injectable protocol is listed for this profile.

Safety context

Reported side effects

Generally well-tolerated
Injection site reactions (mild)
Minimal side effects reported in clinical use

Contraindications & cautions

Active autoimmune diseases (use with caution)
Organ transplant recipients on immunosuppression
Known hypersensitivity to component amino acids
Pregnancy or breastfeeding

Scientific references

01
Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats
Scientific citationImmunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology (2001).
02
Natural and synthetic thymic peptides as therapeutics for immune dysfunction
Scientific citationNatural and synthetic thymic peptides as therapeutics for immune dysfunction. Journal of Immunopharmacology (1997).
03
Peptide Bioregulators from Thymus and Pineal Gland
Scientific citationPeptide Bioregulators from Thymus and Pineal Gland. Biogerontology (2003).
04
Thymogen: Mechanism of Action Studies
Scientific citationThymogen: Mechanism of Action Studies. .

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity